Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Endometrial Carcinoma | Executive Insights | US-EU-JP | 2020

Login to access report north_east
Contact sales account_box

Endometrial cancer is the sixth most common cancer in women worldwide. While the majority of patients present with early stage disease at diagnosis, efficacious therapeutic options for advanced or recurrent disease are scarce. Apart from the combination of Keytruda and Lenvima approved for treatment of certain patient subpopulations, endometrial cancer is predominantly treated with generic chemotherapy. Lack of efficacious treatment options across numerous treatment settings presents enormous market opportunity for drug developers to address with development of targeted therapeutics.

Questions answered:

  • What is the current standard of care for endometrial cancer? What are interviewed experts’ insights on current treatment options? What are the main unmet needs?
  • What are the most promising agents in the late-phase pipeline and most notable in early-phase pipeline? How will these agents shape the future of the endometrial cancer market?
  • How are current therapies reimbursed? What are the key market access considerations for emerging therapies?
  • What are the drivers and constraints of the market?

Scope:

Markets covered: United States, France, Germany, United Kingdom, and Japan.

Primary research: 3 KOL interviews in the United States, 1 each in France, Germany, United Kingdom and Japan.

Key companies covered: Merck & Co., Eisai, AstraZeneca,GlaxoSmithKline, Roche, Karyopharm Therapeutics and others.

Key drugs covered: Keytruda, Imfinzi, Tecentriq, dostarlimab, Lenvima, Xpovio, Lyparza and others.

Product description: Executive Insights provides indication-specific market intelligence with world class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east